- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.
GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the United States between 2019 and 2023. These medications alter glucose metabolism, gastric motility and sympathetic tone, which may lead to unique uptake patterns on PET-CT. Previous case reports have shown increased FDG uptake in skeletal muscle, myocardium and brown adipose tissue, findings that may be mistaken for malignancy or inflammatory disease.
Researchers from Alliance Medical Ltd. performed a retrospective case series review of oncologic FDG PET-CT scans in patients taking GLP-1 agonists. They observed several atypical patterns of tracer uptake that could be misinterpreted as pathology if a patient’s medication history is not considered.
“We noticed unusual uptake in one of our patients on a GLP-1 agonist, which prompted a wider review across our network,” explained lead author Dr Peter Strouhal, Medical Director at Alliance Medical Ltd. “We found that these altered patterns are increasingly common, yet there is currently no national or international guidance in the UK addressing this emerging issue.”
Misinterpreting these uptake patterns can lead to unnecessary investigations, inappropriate cancer staging and delays in treatment, which may cause stress and uncertainty for patients. “Recognising the characteristic uptake associated with GLP-1 agonists helps avoid unnecessary anxiety and interventions, ensuring patients receive the right care, at the right time, without detours or doubt,” Dr Strouhal added.
At present, the researchers do not recommend altering patient preparation or stopping GLP-1 agonists prior to FDG PET-CT scans. Instead, they advise that imaging teams carefully document patients’ medication histories to inform interpretation while formal guidance is developed. Current UK guidelines do not address this issue, although Australian guidance suggests continuing treatment, fasting from midnight, scheduling morning scans and ensuring good glucose control.5
The research group intends to extend their data collection across additional imaging centres to provide a stronger evidence base for future national guidance. They also aim to establish international collaborations so that patients everywhere benefit from consistent and reliable PET-CT interpretation.
Reference:
GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds, Beyond, Meeting: 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25).
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751